NSRX Company Profile and Key Details

NSRX has shown weak momentum, losing -10.68% over the past week and -4.26% over the past quarter, though year-to-date performance is down -28.74%. Short-term trend indicators are bullishly aligned (SMA20 -6.59%, SMA50 -12.66%, SMA200 -18.73%). The stock’s 14-day RSI is 44.57 (neutral), while the ATR of 0.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -39.94% below its high and over 10.7% above its low. Average 10-day trading volume of 6.05 thousand shares is slightly above the 3-month average of 5.34 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $19.00. The high target offers 296.4% upside. The low target suggests 242.34% downside. The mean target is $20.50. This offers 269.37% upside.

Nasus Pharma Ltd. has 9.06 million shares outstanding. The public float is 2.49 million shares, elevated short interest at 0.31% of float. This equals 12.25 thousand shares. The short ratio is 0.09 days. Institutional investors hold 0.0% of the float. Insiders own 59.33%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Nasus Pharma Ltd. (AMEX:NSRX) closed at $5.55 USD, losing -$0.25 (-4.31%) from the previous close of $5.80. The stock is currently within 5% of its 52-week low $5.42 and $9.99. With a market capitalization of about $50.28 million, Nasus Pharma Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~-5.37). Key stats such as the average daily volume over the past year has been around 5.07 thousand shares, volume is running light vs its 52-week average. Headquartered in Tel Aviv, None, Nasus Pharma Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dan Teleman, the company employs approximately 2 people and listed since August 13, 2025. Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose.

Our AI price prediction model suggests that Nasus Pharma Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.05%, with price expected at $4.77 by February 19, 2026, within a range of $4.30 to $5.29 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by May 06, 2026, with a range of $0.00 to $0.06. 1-Year Outlook: Projected loss of -66.49%, with price at $1.86 by February 05, 2027, within a range of $1.79 to $1.96.

Nasus Pharma Ltd. (AMEX:NSRX) shares are down -28.74% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Nasus Pharma Ltd. trading at a premium to the broader market with a P/E of -32.82. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $20.50, suggesting 269.37% upside. Our AI forecast model points to short-term weakness (-14.05% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-66.49% over one year), with expected trading ranges indicating moderate volatility.

Nasus Pharma Ltd. trades at a P/E ratio of -32.82, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at 0.0, also above market averages.